SM 88

Drug Profile

SM 88

Alternative Names: SM-88

Latest Information Update: 09 Feb 2017

Price : $50

At a glance

  • Originator Tyme Technologies
  • Class Small molecules
  • Mechanism of Action Free radical stimulants; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Prostate cancer

Most Recent Events

  • 31 Jan 2017 Tyme Technologies has patent protection for using innovative therapy to treat cancer in USA before January 2017
  • 31 Jan 2017 Tyme Technologies has patent protection for tyrosine in combination with agents that increase oxidative stress in USA
  • 05 Jan 2017 Phase-II clinical trials in Prostate cancer (Second-line therapy or greater) in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top